[go: up one dir, main page]

WO2007116428A8 - Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis - Google Patents

Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis

Info

Publication number
WO2007116428A8
WO2007116428A8 PCT/IT2007/000261 IT2007000261W WO2007116428A8 WO 2007116428 A8 WO2007116428 A8 WO 2007116428A8 IT 2007000261 W IT2007000261 W IT 2007000261W WO 2007116428 A8 WO2007116428 A8 WO 2007116428A8
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
haemodialysis
pharmaceutical composition
composition containing
oxidative stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2007/000261
Other languages
French (fr)
Other versions
WO2007116428A2 (en
WO2007116428A3 (en
Inventor
Francesco Santangelo
Francesco Paolo Pilato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio3 Research Srl
Original Assignee
Bio3 Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Research Srl filed Critical Bio3 Research Srl
Priority to MX2008012974A priority Critical patent/MX2008012974A/en
Publication of WO2007116428A2 publication Critical patent/WO2007116428A2/en
Publication of WO2007116428A8 publication Critical patent/WO2007116428A8/en
Publication of WO2007116428A3 publication Critical patent/WO2007116428A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Described herein is an oral pharmaceutical composition containing cystine or cysteine with glutathione, for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients affected by chronic renal insufficiency.
PCT/IT2007/000261 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis Ceased WO2007116428A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2008012974A MX2008012974A (en) 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000206A ITRM20060206A1 (en) 2006-04-10 2006-04-10 ORAL PHARMACEUTICAL COMPOSITION CONTAINING CYSTINE OR CISTEIN WITH GLUTATHYATE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS FROM HEMODIALYSIS AND MEDICAL ADMINISTRATION DEVICE
ITRM2006A000206 2006-04-10

Publications (3)

Publication Number Publication Date
WO2007116428A2 WO2007116428A2 (en) 2007-10-18
WO2007116428A8 true WO2007116428A8 (en) 2007-12-13
WO2007116428A3 WO2007116428A3 (en) 2008-03-13

Family

ID=38480485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000261 Ceased WO2007116428A2 (en) 2006-04-10 2007-04-06 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis

Country Status (4)

Country Link
KR (1) KR20090024673A (en)
IT (1) ITRM20060206A1 (en)
MX (1) MX2008012974A (en)
WO (1) WO2007116428A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527802B (en) * 2014-07-02 2019-10-16 Olimed Ltd An orally disintegrating tablet with differentiated absorption
FR3092491B1 (en) * 2019-02-11 2021-11-12 Bretagne Chimie Fine Non-therapeutic oral use of a composition for whitening and / or lightening the skin comprising cystine and glutathione in a cystine / glutathione ratio ranging from 1.5 to 4
US20230372272A1 (en) * 2020-09-28 2023-11-23 Georgia Tech Research Corporation Use of cystine and derivatives thereof as anti-thrombotic and thrombolytic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146265B1 (en) * 1983-11-15 1991-04-03 Kyowa Hakko Kogyo Co., Ltd. Process for producing a compound from its precursor using an enzymatic activity of bacterium
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
KR100390630B1 (en) * 1999-07-02 2003-07-07 이희발 Peritoneal dialysis solutions containing antioxidants
ITMI20032528A1 (en) * 2003-12-19 2005-06-20 Francesco Santangelo USE OF CYSTINE OR CISTEIN FOR PREVENTION AND THE

Also Published As

Publication number Publication date
WO2007116428A2 (en) 2007-10-18
MX2008012974A (en) 2008-12-18
WO2007116428A3 (en) 2008-03-13
KR20090024673A (en) 2009-03-09
ITRM20060206A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
EA201100958A1 (en) PHARMACEUTICAL ORAL DOSED DOSAGE FORM BASED ON DPP IV INHIBITORS
EA200701146A1 (en) COMPOSITION CONTAINING ORNITIN AND PHENYL ACETATE OR PHENYBUTIRATE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EA201200968A1 (en) USE OF TRANS-CLOMIPHENE FOR THE PREVENTION OR TREATMENT OF DIABETES TYPE 2 IN MEN
ES2356883A1 (en) Compositions for the treatment of pain and/or inflamation
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
WO2008022974A3 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
MX2010001849A (en) Cyclic depsipeptides.
WO2008046865A3 (en) Long-term feed - elderly
WO2005077103A3 (en) Compositions and methods for modification and prevention of sars coronavirus infectivity
WO2008017752A3 (en) Eucalyptus extract, method of preparation and therapeutic uses thereof
WO2009068708A3 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007116428A3 (en) Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis
TW200700071A (en) Novel use
EP2193789B8 (en) The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
EA200702336A1 (en) APPLICATION 24-NorUDK
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
EP1997503A3 (en) Treatment of melanoma with alpha thymosin peptides
EA200970877A1 (en) COMPOSITION SUITABLE FOR THE PREVENTION OF TYPE 2 DIABETES AND ITS COMPLICATIONS IN PATIENTS WITH PREDIABETES WITH INSULIN RESISTANCE
EP1843781A4 (en) Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EA200970798A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES TYPE 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012974

Country of ref document: MX

Ref document number: 4082/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087027326

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2